Blood glucose monitoring should increase to 4-6 times daily during the first month of combination therapy, with particular attention to pre-meal and bedtime readings
While these medications are FDA-approved for obesity (BMI 30 kg/m or 27 kg/m with weight-related complications) and/or type 2 diabetes, they are not specifically approved for MASLD/MASH treatment
Relative treatment effects of combination therapy assuming 50% additivity were modestly attenuated: MACE (HR, 0.73 [95% CI, 0.620.87]), heart failure hospitalization (HR, 0.53 [95% CI, 0.410.70]), CKD progression (HR, 0.51 [95% CI, 0.380.68]), cardiovascular death (HR, 0.73 [95% CI, 0.580.92]), and all-cause mortality (HR, 0.75 [95% CI, 0.630.90])
Topical copper peptides are designed to work on the skins surface and within the skin itself, while dietary copper is absorbed through the digestive system and becomes available to the hundreds of copper-dependent enzymes that support normal function throughout the entire body
The San Diego company is testing both an injectable and pill form
Margaret McCarthy discusses the genetics of autism, how to interpret associations in health studies, and why medical guidance matters